Trevi Therapeutics (TRVI) Operating Income (2018 - 2025)
Trevi Therapeutics' quarterly Operating Income came in at -$10.2 million in Q4 2025, up 16.52% year-on-year from -$8.8 million in Q4 2024, and up 26.56% quarter-over-quarter from -$13.9 million in Q3 2025.
Trevi Therapeutics has reported Operating Income for 8 years, with the latest figure at -$10.2 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income rose 16.52% year-over-year to -$10.2 million; the trailing twelve-month figure through Dec 2025 stood at -$50.1 million (up 2.76% YoY), and the FY2025 full-year result was -$49.3 million, up 4.26% from the prior year.
- Operating Income for Q4 2025 stood at -$10.2 million, up from -$13.9 million in the prior quarter.
- The five-year high for Operating Income was -$6.7 million in Q4 2022, with the low at -$14.1 million in Q3 2024.
- Average Operating Income over 5 years is -$9.8 million, with a median of -$8.9 million recorded in 2023.
- Year-over-year, Operating Income rose 19.53% in 2022 and plunged 58.54% in 2024.
- Tracing TRVI's Operating Income over 5 years: stood at -$8.3 million in 2021, then gained by 19.53% to -$6.7 million in 2022, then plunged by 34.19% to -$8.9 million in 2023, then plunged by 37.05% to -$12.2 million in 2024, then advanced by 16.52% to -$10.2 million in 2025.
- The last three Operating Income figures came in at -$10.2 million (Q4 2025), -$13.9 million (Q3 2025), and -$13.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.22 Mn |
| Sep 30, 2025 | -13.92 Mn |
| Jun 30, 2025 | -13.72 Mn |
| Dec 31, 2024 | -12.24 Mn |
| Sep 30, 2024 | -14.09 Mn |
| Jun 30, 2024 | -13.29 Mn |
| Mar 31, 2024 | -11.91 Mn |
| Dec 31, 2023 | -8.93 Mn |
| Sep 30, 2023 | -9.05 Mn |
| Jun 30, 2023 | -8.38 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -6.66 Mn |
| Sep 30, 2022 | -8.41 Mn |
| Jun 30, 2022 | -7.82 Mn |
| Mar 31, 2022 | -7.03 Mn |
| Dec 31, 2021 | -8.27 Mn |
| Sep 30, 2021 | -6.95 Mn |
| Jun 30, 2021 | -9.17 Mn |
| Mar 31, 2021 | -8.09 Mn |
| Dec 31, 2020 | -9.19 Mn |
| Sep 30, 2020 | -7.24 Mn |
| Jun 30, 2020 | -7.41 Mn |
| Mar 31, 2020 | -8.64 Mn |
| Dec 31, 2019 | -6.77 Mn |
| Sep 30, 2019 | -7.65 Mn |
| Jun 30, 2019 | -7.42 Mn |
| Mar 31, 2019 | -4.81 Mn |
| Dec 31, 2018 | -5.93 Mn |
| Sep 30, 2018 | -4.96 Mn |
| Jun 30, 2018 | -4.38 Mn |
| Mar 31, 2018 | -3.14 Mn |